Eyenovia

140 articles about Eyenovia

• Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

  4/8/2024

  Eyenovia, Inc., a commercial-stage ophthalmic company, announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia and initiated a process to explore strategic alternatives to maximize shareholder value.

• Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

  4/3/2024

  Eyenovia, Inc., a commercial-stage ophthalmic company, announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

• Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

  3/18/2024

  Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2023.

• NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

  3/13/2024

  NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05%, a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.

• Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

  3/11/2024

  Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the markets close.

• 

  Eyenovia, Formosa Win FDA Approval for Anti-Inflammatory Eye Drops

  3/5/2024

  The regulator has approved Eyenovia and Formosa’s ophthalmic clobetasol propionate solution to ease eye inflammation and pain after surgery, with a potential $1.3 billion market.

• Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

  3/5/2024

  Eyenovia, Inc. today congratulates Formosa Pharmaceuticals (TWO:6838) on the FDA approval of clobetasol propionate ophthalmic suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery.

• 

  FDA Action Alert: Vanda, Eyenovia and Viatris/Mapi

  3/4/2024

  The FDA will kick off March with three target action dates, including one for an insomnia treatment and another for a multiple sclerosis therapy.

• Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

  2/13/2024

  Eyenovia, Inc. announced that the company’s facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility.

• Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

  1/16/2024

  Eyenovia, Inc., a commercial-stage, ophthalmic company, announced that it has re-acquired the rights to MicroPine in the U.S. and Canada.

• Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/13/2023

  Eyenovia, Inc. announced its financial and operating results for the third quarter ended September 30, 2023.

• Eyenovia to Report Third Quarter 2023 Results on Monday, November 13Company to host an investor conference call and webcast at 4:30pm EDT

  11/6/2023

  Eyenovia, Inc. announced that the Company will release financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023, after the markets close.

• Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial ProductionAnticipates having product available to ship in January 2024

  11/2/2023

  Eyenovia, Inc. announced that the FDA has approved Eyenovia’s Supplemental New Drug Application, adding Coastline International as a contract manufacturer.

• Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

  10/9/2023

  Eyenovia, Inc. announced that it will deliver a presentation on the microbial integrity of its Optejet dispensing device at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting, which is being held October 11-14, 2023.

• Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference

  9/21/2023

  Eyenovia, Inc. today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.

• Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

  9/7/2023

  Eyenovia, Inc. today announced management will deliver a presentation at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place on September 11-13, 2023 at the Lotte New York Palace Hotel.

• Eyenovia Announces $12 Million Registered Direct Offering

  8/24/2023

  Eyenovia, Inc. announced that it has entered into a Securities Purchase Agreement with a leading health care investor in an offering of 4,198,633 shares of its common stock, pre-funded warrants to purchase up to 2,252,979 shares of common stock and warrants to purchase up to 4,838,709 shares of common stock.

• Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

  8/16/2023

  Taiwan-based Formosa Pharmaceuticals announced that the company has entered into a licensing agreement with Eyenovia, Inc., whereby Eyenovia obtains exclusive U.S. rights for the commercialization of APP13007 for the treatment of inflammation and pain following ocular surgery.

• Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

  8/16/2023

  Eyenovia, Inc. announced that it has entered into an agreement with Taiwan-based Formosa Pharmaceuticals whereby Eyenovia has acquired the exclusive U.S. Food and Drug Administration,

• Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/10/2023

  Eyenovia, Inc. announced its financial and operating results for the second quarter ended June 30, 2023.